2 weeks Ago By Defense World Staff
Commonwealth Equity Services LLC trimmed its holdings in Charles River Laboratories International, Inc. ( NYSE:CRL – Free Report ) by 14.0% in the 4th quarter, according to its most recent filing with the SEC.
The institutional investor owned 11,853 shares of the medical research company’s stock after selling 1,932 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Charles River Laboratories International were worth $2,188,000 at the end of the most recent reporting period. A number of other hedge funds have also bought and sold shares of CRL.
Impact Capital Partners LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $422,000. Truvestments Capital LLC grew its position in Charles River Laboratories International by 6.4% in the 4th quarter.
Truvestments Capital LLC now owns 2,562 shares of the medical research company’s stock worth $473,000 after purchasing an additional 155 shares during the period. EverSource Wealth Advisors LLC raised its stake in Charles River Laboratories International by 10.2% during the 4th quarter.
EverSource Wealth Advisors LLC now owns 1,673 shares of the medical research company’s stock valued at $309,000 after buying an additional 155 shares during the last quarter. Cooke & Bieler LP lifted its holdings in shares of Charles River Laboratories International by 42.1% during the 4th quarter.
Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock valued at $78,781,000 after buying an additional 126,372 shares during the period. Finally, Tortoise Investment Management LLC grew its holdings in shares of Charles River Laboratories International by 77.7% in the fourth quarter.
Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after acquiring an additional 115 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.
Analysts Set New Price Targets A number of research analysts have weighed in on the company. Robert W. Baird lowered their target price on Charles River Laboratories International from $177.
00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.
00 to $170.00 in a research note on Friday, March 21st. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the company from $155.
00 to $175.00 in a research report on Tuesday, March 4th. UBS Group reiterated a “neutral” rating and issued a $185.
00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, Barclays reduced their price objective on Charles River Laboratories International from $205.
00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock.
According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $189.77. Insider Buying and Selling In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th.
The shares were bought at an average price of $164.63 per share, with a total value of $249,249.82.
Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.
83 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website . Also, EVP Joseph W.
Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.
00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50.
The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
1.30% of the stock is owned by company insiders. Charles River Laboratories International Stock Down 0.
0 % NYSE CRL opened at $158.25 on Friday. The company has a current ratio of 1.
41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.
Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $273.
32. The stock’s 50 day moving average is $164.85 and its 200 day moving average is $182.
96. The stock has a market cap of $8.09 billion, a PE ratio of 1,054.
99, a P/E/G ratio of 4.54 and a beta of 1.45.
Charles River Laboratories International ( NYSE:CRL – Get Free Report ) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.
50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.
63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.
69%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year.
During the same quarter in the previous year, the firm earned $2.46 earnings per share. Research analysts predict that Charles River Laboratories International, Inc.
will post 9.36 EPS for the current fiscal year. Charles River Laboratories International Company Profile ( Free Report ) Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). See Also Five stocks we like better than Charles River Laboratories International 2 Fintech Stocks to Buy Now and 1 to Avoid Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell Low PE Growth Stocks: Unlocking Investment Opportunities Top 3 Beverage Stocks Pouring Out Profits Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours? CarMax and Carvana: Steering the Used Car Market Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. ( NYSE:CRL – Free Report ). Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.
com's FREE daily email newsletter ..
